Immunodiagnostic Systems Holdings PLC
IDS LISA-TRACKER - Model LTI-005 - Duo Infliximab Manual Immunoassays
LISA-TRACKER Duo Infliximab is an enzyme linked immunoassay (ELISA) for the quantitative determination of Infliximab (anti-TNFα) and anti-Infliximab antibodies in human serum samples.
Most popular related searches
therapeutic drug monitoring
inflammatory disease
immunoassay
arthritis crohn
drug monitoring
disease symptoms
inflammatory state
immunoassay ELISA
human serum
monoclonal antibody
Anti-TNFα are therapeutic agents widely used to treat patients with various inflammatory diseases. Infliximab is one of the anti-TNFα recommended for the treatment of the rheumatoid arthritis, Crohn’s disease, ankylosing spondylitis, etc. This chimeric monoclonal antibody is able to bind TNFα. It blocks the action of TNFα responsible for the inflammatory state. However, during the treatment, some patients can develop antibodies against Infliximab. Consequently, the plasma level of anti-TNFα decreases and simultaneous the disease symptoms reappear or increase.
- Comprehensive menu in inflammatory diseases and oncology
- Standardised against the 1st International standard (16/170)
- Validated on principle drug and biosimilars
- Ready to use reagents
- Standardised protocols from sample collection to result interpretation
- Automation ready – validated on several open platform ELISA systems
- Product Code: LTI-005
- Certification: CE Marked
- Clinical Area: Therapeutic Drug Monitoring Solutions
- Type: Manual
- Format: ELISA
- RUO/IVD: IVD
- Number of Tests: 2 x 48
- Sample Type: Serum
- Sample Volume: 100 μL (following predilution)
- Assay Range: Infliximab: 0.3 – 20 μg/mL
- Anti-Infliximab: 10 – 200 ng/mL